Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy

Summary

Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.

Eligibility

Inclusion Criteria:

* Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC
* Indication for neoadjuvant chemotherapy
* Candidates for curative breast surgery
* Body mass index: 18.5 \<BMI \<30 kg/m2
* Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week)
* Willingness to participate in the study and follow the proposed prehabilitation scheme.

Exclusion Criteria:

* Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others).
* Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50%
* Previous antineoplastic treatment
* Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).

Conditions5

Browse More Trials